Arkolith/Insider Trading/RXDX/Form 4

McKenna Mark C.

Chairman, President & CEO, DirectorPrometheus Biosciences, Inc. (RXDX) · full profile →Form 4 · filed Feb 17, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7.7M
Net Open-Market Flow
-$7.7M
Transactions
9
6 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 17, 2023Option exercise(M)14K$3.70$51K69K
Feb 17, 2023Sell(S)14K$125.10$1.7M55K
Feb 16, 2023Sell(S)25K$119.87$3.0M55K
Feb 16, 2023Option exercise(M)25K$3.70$93K80K
Feb 15, 2023Option exercise(M)25K$2.90$73K80K
Feb 15, 2023Sell(S)25K$119.42$3.0M55K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 17, 2023Option exercise(M)14K—$0493K
Feb 16, 2023Option exercise(M)25K—$0507K
Feb 15, 2023Option exercise(M)25K—$0309K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-010972) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML